Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + pertuzumab + taselisib + trastuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of paclitaxel (a taxane chemotherapy), pertuzumab and trastuzumab (HER2-targeted monoclonal antibodies), and taselisib (a PI3K inhibitor). This regimen targets multiple pathways in HER2-positive breast cancer: paclitaxel disrupts cell division by stabilizing microtubules; pertuzumab and trastuzumab bind to different regions of the HER2 receptor to block signaling; and taselisib inhibits the PI3K pathway that promotes cancer cell growth. This combination has been investigated in clinical trials for patients with HER2-positive metastatic breast cancer.
02
Targets
MicrotubuleERBB2 (Erb-b2 receptor tyrosine kinase 2)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on paclitaxel + pertuzumab + taselisib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + pertuzumab + taselisib + trastuzumab.